Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2014 Financial Results

  Opexa Therapeutics Announces News Release and Conference Call Schedule to
  Discuss Second Quarter 2014 Financial Results

Business Wire

THE WOODLANDS, Texas -- August 11, 2014

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing
Tcelna^®, a novel T-cell immunotherapy for the treatment of secondary
progressive multiple sclerosis (SPMS), today announced that the Company will
report financial results for the three months ended June 30, 2014 after the
close of trading on Thursday, August 14th. The Company will also conduct a
conference call and webcast to discuss financial results and provide a
corporate update at 5:00 P.M. EDT on Thursday, August 14th.

Conference Call and Webcast Details

To listen to the conference call, dial in approximately ten minutes before the
scheduled 5:00 P.M. time to (253)237-1170 or toll free at (877) 372-0867.
Please reference conference ID 81938581 or the Opexa Therapeutics Earnings
Call.

A live webcast of the call can also be accessed here or via the webcast link
on the Investor Relations page of Opexa's website (www.opexatherapeutics.com).

There will be a brief Question & Answer session following management
commentary.

About Opexa

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning
the interests of patients, employees and shareholders. The Company’s leading
therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy that is in
a Phase IIb clinical development program (the Abili-T trial) for the treatment
of Secondary Progressive MS. Tcelna is derived from T-cells isolated from a
patient’s peripheral blood, expanded ex vivo, and reintroduced into the
patient via subcutaneous injections. This process triggers a potent immune
response against specific subsets of autoreactive T-cells known to attack
myelin.

About Multiple Sclerosis (MS)

MS is a chronic, inflammatory condition of the central nervous system and is
the most common, non-traumatic, disabling neurological disease in young
adults. It is estimated that approximately two million people have MS
worldwide.

While symptoms can vary, the most common symptoms of MS include blurred
vision, numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common. The Secondary
Progressive form of MS represents about a third of the MS patient population.

About Tcelna

Tcelna^® is a potential personalized therapy that is under development to be
specifically tailored to each patient's disease profile. Tcelna is
manufactured using ImmPath^®, Opexa's proprietary method for the production of
a patient-specific T-cell immunotherapy, which encompasses the collection of
blood from the MS patient, isolation of peripheral blood mononuclear cells,
generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised
against selected peptides from myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the
return of these expanded, irradiated T-cells back to the patient. These
attenuated T-cells are reintroduced into the patient via subcutaneous
injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna. Named “Abili-T,”
the trial is a randomized, double-blind, placebo-controlled clinical study in
patients who demonstrate evidence of disease progression with or without
associated relapses. The trial is being conducted at approximately 35 leading
clinical sites in the U.S. and Canada with each patient receiving two annual
courses of Tcelna treatment consisting of five subcutaneous injections per
year. The trial’s primary efficacy outcome is the percentage of brain volume
change (atrophy) at 24 months. Study investigators will also measure several
important secondary outcomes commonly associated with MS, including disease
progression as measured by the Expanded Disability Status Scale (EDSS),
annualized relapse rate and changes in disability as measured by EDSS and the
MS Functional Composite.

For more information visit the Opexa Therapeutics website at
www.opexatherapeutics.com.

Contact:

Company Contact:
Opexa Therapeutics, Inc.
Karthik Radhakrishnan, 281-775-0600
Chief Financial Officer
or
Investor Relations:
The Trout Group
Adam Cutler, 646-378-2936
opexa@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.